Publications by authors named "Sherin P Mathew"
Article Synopsis
- Newer anti-Her2 medications are limited in access, leading to the prevalent use of lapatinib, which has a high financial burden for patients in low-income areas.
- A study in South India tested a low-dose lapatinib regimen (500 mg daily with meals) on patients who couldn't afford standard treatments, showing promising disease control rates and manageable toxicity.
- Among 47 patients, the disease control rate was 61.7% with a median progression-free survival of 7 months, indicating low-dose lapatinib could be a viable option in resource-constrained settings.
Extranodal lymphomas constitute 20% to 30% of all non-Hodgkin's lymphomas. The common sites involved are skin, stomach, brain, and small intestine. Epidural localization is a rare site for lymphomas, accounting for 10% of spinal epidural tumors.
View Article and Find Full Text PDF